This analysis aims to assess the efficacy and safety of tofacitinib and adalimumab in rheumatoid arthritis when normalized by methotrexate dosing based on body mass index.
Conducted a post hoc analysis of trial data from NCT02187055.
Examined the efficacy and safety profiles of tofacitinib and adalimumab.
Normalized methotrexate doses according to body mass index.
Tofacitinib and adalimumab showed differing efficacy based on normalized methotrexate dosing.
Safety profiles were comparable between both treatment groups.
Variations in patient body mass index influenced treatment outcomes.
Abstract
ClinicalTrials.gov identifier, NCT02187055.
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis | Synapse